Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors
Completed · Phase 1/Phase 2
Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of docetaxel and irinotecan in treating patients who have advanced solid tumors.
Key facts
- Study ID
- NCT00004923
- Run by
- Yale University
- People needed
- 47
- Starts
- 1999-04-01
- Expected to finish
- 2006-05-01
- Last updated by the study team
- 2009-08-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Yale Comprehensive Cancer Center — New Haven, Connecticut, United States
- Bennett Cancer Center — Stamford, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.